Your browser doesn't support javascript.
loading
EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib.
Zhang, Qi; Zhang, Xu-Chao; Yang, Jin-Ji; Yang, Zhen-Fan; Bai, Yu; Su, Jian; Wang, Zheng; Zhang, Zhou; Shao, Yang; Zhou, Qing; Kang, Jin; Ke, E-E; Zhang, Yi-Chen; Dong, Zhong-Yi; Chen, Zhi-Hong; Tu, Hai-Yan; Zhong, Wen-Zhao; Yang, Xue-Ning; Wu, Yi-Long.
Afiliación
  • Zhang Q; Southern Medical University, Guangzhou, People's Republic of China; Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China.
  • Zhang XC; Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China.
  • Yang JJ; Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China.
  • Yang ZF; Dizal (Jiangsu) Pharmaceutical, Bioscience Wuxi, Jiangsu, People's Republic of China.
  • Bai Y; Dizal (Jiangsu) Pharmaceutical, Bioscience Wuxi, Jiangsu, People's Republic of China.
  • Su J; Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China.
  • Wang Z; Asia Innovative Medicines and Early Development, AstraZeneca, Shanghai, People's Republic of China.
  • Zhang Z; Burning Rock Biotech, Guangzhou, Guangdong Province, People's Republic of China.
  • Shao Y; Geneseeq Biotechnology, Inc., Nanjing, People's Republic of China.
  • Zhou Q; Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China.
  • Kang J; Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China.
  • Ke EE; Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China.
  • Zhang YC; Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China.
  • Dong ZY; Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China.
  • Chen ZH; Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China.
  • Tu HY; Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China.
  • Zhong WZ; Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China.
  • Yang XN; Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China.
  • Wu YL; Southern Medical University, Guangzhou, People's Republic of China; Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China. Electronic address: syylwu@live.cn.
J Thorac Oncol ; 13(9): 1415-1421, 2018 09.
Article en En | MEDLINE | ID: mdl-29857056
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Acrilamidas / Inhibidores de Proteínas Quinasas / Adenocarcinoma del Pulmón / Compuestos de Anilina / Mutación Tipo de estudio: Observational_studies / Prognostic_studies Límite: Female / Humans / Middle aged Idioma: En Revista: J Thorac Oncol Año: 2018 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Acrilamidas / Inhibidores de Proteínas Quinasas / Adenocarcinoma del Pulmón / Compuestos de Anilina / Mutación Tipo de estudio: Observational_studies / Prognostic_studies Límite: Female / Humans / Middle aged Idioma: En Revista: J Thorac Oncol Año: 2018 Tipo del documento: Article Pais de publicación: Estados Unidos